NEW BRUNSWICK, N.J. - Johnson & Johnson's subsidiary, Red River Talc LLC, has filed for a prepackaged Chapter 11 bankruptcy as part of a strategy to resolve all current and future ovarian cancer claims related to cosmetic talc litigation in the United States. The bankruptcy filing, which took place today, comes after Red River secured the support of approximately 83% of current claimants for its proposed bankruptcy plan, surpassing the 75% approval threshold required by the U.S. Bankruptcy Code.
The plan also received backing from an attorney representing future claimants, known as the Future Claims Representative. Red River's commitment to the settlement increased by $1.75 billion, bringing the total to an estimated $8 billion. The company has agreed to back Red River's commitments, including an additional $1.1 billion to the bankruptcy trust for claimants and $650 million to cover legal fees and expenses.
The proposed settlement, which is expected to be paid over 25 years, has a present value of approximately $8 billion, amounting to a nominal total of about $10 billion. According to Erik Haas, Worldwide Vice President of Litigation at Johnson & Johnson, the plan is fair and equitable and should be confirmed expeditiously by the Bankruptcy Court. He emphasized that the plan offers claimants a better recovery than they would likely receive at trial, noting that the company has won approximately 95% of ovarian cases tried to date.
The plan aims to resolve 99.75% of all pending talc lawsuits against Johnson & Johnson and its affiliates in the United States, with the remaining 0.25% of cases related to mesothelioma being addressed separately. This move follows previous settlements reached by the company with state consumer protection claims and other talc-related claims in bankruptcy cases filed by its talc suppliers.
Johnson & Johnson maintains that the talc-related claims against it are without merit, citing decades of independent expert analysis and regulatory bodies' findings supporting the safety of talc. Additional information on the company's stance and the science behind talc safety can be found at www.FactsAboutTalc.com.
The information for this article is based on a press release statement.
In other recent news, Johnson & Johnson's subsidiary, J&J Red River Talc, has filed for bankruptcy as part of an $8 billion settlement strategy aimed at resolving tens of thousands of lawsuits. The lawsuits claim that the company's talc products, including its baby powder, were contaminated with asbestos, leading to various cancers. In a separate legal development, an Oregon judge has ordered a new trial in a case involving a $260 million verdict against Johnson & Johnson concerning claims that its talc powder caused mesothelioma.
In financial analysis, Goldman Sachs reiterated its Buy rating on shares of CG Oncology, citing limited downside risk following new data presented by Johnson & Johnson. The data concerned the Phase 3 SunRISe-1 study of TAR-200, with or without cetrelimab, in patients with BCG-unresponsive non-muscle invasive bladder cancer.
On the medical front, Johnson & Johnson announced significant findings from their Phase 2 SKIPPirr study, indicating a substantial reduction in infusion-related reactions in patients with advanced non-small cell lung cancer treated with RYBREVANT®. In other recent developments, the company announced the retirement of D. S. Davis from its board of directors and the retirement of Executive Vice President and Chief Human Resources Officer, Dr. Peter M. Fasolo. Kristen Mulholland will succeed Dr. Fasolo. These developments reflect a period of executive transition, legal resolution, and ongoing pharmaceutical innovation at Johnson & Johnson.
InvestingPro Insights
As Johnson & Johnson (JNJ) navigates the complexities of the cosmetic talc litigation through its subsidiary's bankruptcy filing, investors and stakeholders are keeping a close eye on the company's financial health and market position. Our InvestingPro Insights reveal some key metrics that may influence perceptions of the company's stability and future prospects.
Johnson & Johnson is currently trading at a low P/E ratio of 10.51, which suggests that the stock may be undervalued relative to its near-term earnings growth. This could be an attractive entry point for investors looking for value in the healthcare sector. Additionally, the company's reputation as a prominent player in the Pharmaceuticals industry, coupled with its long history of dividend reliability—having raised its dividend for 53 consecutive years—underscores its commitment to shareholder returns.
InvestingPro Data indicates that JNJ's market capitalization stands at a robust $394.96 billion, reflecting the company's size and influence in the market. Furthermore, the company has demonstrated solid financial performance with a revenue growth of 5.13% over the last twelve months as of Q1 2023. This growth is supported by a substantial gross profit margin of 69.43%, highlighting the company's efficiency in managing its cost of goods sold.
For investors looking for additional insights, there are over 10 InvestingPro Tips available for JNJ, which include analyses on earnings revisions, stock volatility, debt levels, and profitability. These tips can be accessed through the InvestingPro platform for those seeking deeper analysis to inform their investment decisions.
Johnson & Johnson's strategic approach to resolving litigation claims, combined with its solid financial metrics, suggests a company that is not only addressing its current challenges but also maintaining its focus on long-term growth and shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.